CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 185 filers reported holding CHINOOK THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 7.73 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $111,699,119 | +79.5% | 2,907,317 | +8.2% | 0.01% | +50.0% |
| Q1 2023 | $62,228,311 | -55.3% | 2,688,048 | -49.5% | 0.00% | 0.0% |
| Q4 2022 | $139,329,294 | +187.4% | 5,317,912 | +115.7% | 0.00% | +33.3% |
| Q3 2022 | $48,476,000 | +78.5% | 2,465,719 | +58.8% | 0.00% | +50.0% |
| Q2 2022 | $27,161,000 | +4.0% | 1,552,941 | -2.8% | 0.00% | +100.0% |
| Q1 2022 | $26,127,000 | +24.4% | 1,597,002 | +24.0% | 0.00% | 0.0% |
| Q4 2021 | $21,001,000 | +17.7% | 1,287,640 | -7.9% | 0.00% | 0.0% |
| Q3 2021 | $17,841,000 | +34.4% | 1,398,169 | +48.7% | 0.00% | 0.0% |
| Q2 2021 | $13,274,000 | +222.4% | 940,106 | +254.9% | 0.00% | – |
| Q1 2021 | $4,117,000 | -9.4% | 264,900 | -7.5% | 0.00% | – |
| Q4 2020 | $4,543,000 | – | 286,457 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $119,497,707 | 24.70% |
| Saturn V Capital Management LP | 506,818 | $11,732,837 | 8.76% |
| Octagon Capital Advisors LP | 2,551,703 | $59,071,924 | 8.50% |
| Affinity Asset Advisors, LLC | 976,021 | $22,594,886 | 7.46% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $100,599,691 | 7.28% |
| Altium Capital Management LP | 305,000 | $7,060,750 | 3.92% |
| Deep Track Capital, LP | 3,000,000 | $69,450,000 | 2.85% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 319,989 | $7,407,745 | 2.07% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,637,943 | 1.80% |
| Nicholas Investment Partners, LP | 972,191 | $22,506,222 | 1.71% |